http://www.pharmaasia.comPharmaAsia - Latest Updatesen-USCopyright 2012 Ten Alps Communications Asia. All rights reserved.Thu, 24 May 2012 12:41:44 +0800http://www.pharmaasia.com/article/new-pulmonary-embolism-treatments-offer-patients-freedom-from-needles/9400Treatments for pulmonary embolisms (PE) will evolve to better suit patient needs and enhance their quality of life, according to a report by GlobalData.http://www.pharmaasia.com/article/new-pulmonary-embolism-treatments-offer-patients-freedom-from-needles/9400Thu, 24 May 2012 00:00:00 +0800http://www.pharmaasia.com/article/global-generic-drug-markets-will-grow-to-us-221-billion-by-2016/9399Driven by the need to control costs, the use of generic drugs has grown considerably in recent years, even in markets where traditionally they have not been favored.http://www.pharmaasia.com/article/global-generic-drug-markets-will-grow-to-us-221-billion-by-2016/9399Wed, 23 May 2012 00:00:00 +0800http://www.pharmaasia.com/article/global-generic-drug-markets-will-grow-to-us-221-billion-by-2016/9399Driven by the need to control costs, the use of generic drugs has grown considerably in recent years, even in markets where traditionally they have not been favored.http://www.pharmaasia.com/article/global-generic-drug-markets-will-grow-to-us-221-billion-by-2016/9399Wed, 23 May 2012 00:00:00 +0800http://www.pharmaasia.com/article/astellas-site-implements-werum-s-pas-x/9398The MES will introduce efficient and state-of-the-art paperless electronic batch recording functionality supporting compliant, efficient and lean production processes.http://www.pharmaasia.com/article/astellas-site-implements-werum-s-pas-x/9398Tue, 22 May 2012 00:00:00 +0800http://www.pharmaasia.com/article/astellas-site-implements-werum-s-pas-x/9398The MES will introduce efficient and state-of-the-art paperless electronic batch recording functionality supporting compliant, efficient and lean production processes.http://www.pharmaasia.com/article/astellas-site-implements-werum-s-pas-x/9398Tue, 22 May 2012 00:00:00 +0800http://www.pharmaasia.com/article/burgopak-launch-chrysalis-carton-in-partnership-with-medica-packaging/9397The solution connects the outer carton and patient information leaflet (PIL) conveniently together. The patient pulls a perforated flap on the carton to expose the patient leaflet, which they can unfold to display the product information.http://www.pharmaasia.com/article/burgopak-launch-chrysalis-carton-in-partnership-with-medica-packaging/9397Mon, 21 May 2012 00:00:00 +0800http://www.pharmaasia.com/article/burgopak-launch-chrysalis-carton-in-partnership-with-medica-packaging/9397The solution connects the outer carton and patient information leaflet (PIL) conveniently together. The patient pulls a perforated flap on the carton to expose the patient leaflet, which they can unfold to display the product information.http://www.pharmaasia.com/article/burgopak-launch-chrysalis-carton-in-partnership-with-medica-packaging/9397Mon, 21 May 2012 00:00:00 +0800http://www.pharmaasia.com/article/burgopak-launch-chrysalis-carton-in-partnership-with-medica-packaging/9397The solution connects the outer carton and patient information leaflet (PIL) conveniently together. The patient pulls a perforated flap on the carton to expose the patient leaflet, which they can unfold to display the product information.http://www.pharmaasia.com/article/burgopak-launch-chrysalis-carton-in-partnership-with-medica-packaging/9397Mon, 21 May 2012 00:00:00 +0800http://www.pharmaasia.com/article/us-supreme-court-clears-way-for-generic-patent-challenges/9396After the ruling, generic manufacturers will now be able to challenge the content of patent descriptions and, if successful, ultimately force approval of the ANDA. Writing for the Court in a unanimous decision, Justice Elena Kagan chastised the FDA for using ambiguous or opaque guidelines and forms that lend to the confusion surrounding patent decisions.http://www.pharmaasia.com/article/us-supreme-court-clears-way-for-generic-patent-challenges/9396Fri, 18 May 2012 00:00:00 +0800http://www.pharmaasia.com/article/us-supreme-court-clears-way-for-generic-patent-challenges/9396After the ruling, generic manufacturers will now be able to challenge the content of patent descriptions and, if successful, ultimately force approval of the ANDA. Writing for the Court in a unanimous decision, Justice Elena Kagan chastised the FDA for using ambiguous or opaque guidelines and forms that lend to the confusion surrounding patent decisions.http://www.pharmaasia.com/article/us-supreme-court-clears-way-for-generic-patent-challenges/9396Fri, 18 May 2012 00:00:00 +0800